drugset / Trial / NCT06180174
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
Phase 1
Recruiting
24 enrolled
Chongqing Precision Biotech Co., Ltd
Peking University Cancer Hospital & Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, dose-escalation phase I clinical study to explore the safety, tolerability, and cytokinetic characteristics of MC-1-50 cell formulation, and to preliminarily observe the efficacy of MC-1-50 cell formulation in subjects with relapsed/refractory CD19-positive B-cell non-Hodgkin lymphoma.
Timeline
- Start
- 2023-12-31
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MC-1-50 | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | MC-1-50 | Cell therapy | 300000 cells/kg | Intravenous |
| Subject | MC-1-50 | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | MC-1-50 | Cell therapy | 1e+06 cells/kg | Intravenous |